NeuroOne Medical Technologies Corporation - Common Stock (NMTC)

NeuroOne submits FDA filing early for trigeminal nerve ablation using its OneRF system as the facial pain market sees projected growth to $416 million by 2030.

Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Friday.

As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

U.S. stock futures continued to decline on Friday after a bloodbath on Thursday following the introduction of Donald Trump's tariffs.

Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.

NMTC stock results show that NeuroOne Medical Tech met analyst estimates for earnings per share but missed on revenue for the third quarter of 2024.

Given the high bar to developing good neuroscience drugs, firms that do so will likely succeed. Here are three top biotech stocks to buy now. 

These neurotech stocks stand at the cutting edge of healthcare, but early entrants in new fields tend to be long-term winners.

NMTC stock results show that NeuroOne Medical Tech missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

--News Direct--

--News Direct--

--News Direct--